Pterostilbene Inhibits Human Multiple Myeloma Cells via ERK1/2 and JNK Pathway In Vitro and In Vivo

International Journal of Molecular Sciences

Weiliang Zhu¹  Yong Zhang¹  Zhijian Xu¹  Bo Li¹  Bojie Dai²  Guang Yang³  Huiqun Wu³  Yi Tao³  Liangning Hu³  Bingqian Xie³  Jumei Shi³  Rong Wei³  Gaomei Chang³  Xi Sun³  Gege Chen³ 

[1] CAS Key Laboratory of Receptor Research, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China;College of Life Science and Technology, Tongji University, Shanghai 200092, China;Department of Hematology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China;

关键词: multiple myeloma;    pterostilbene;    apoptosis;    cell cycle;    ERK1/2;    JNK;   

DOI  :  10.3390/ijms17111927

来源: DOAJ

【 摘 要 】

Multiple myeloma (MM) is the second most common malignancy in the hematologic system, which is characterized by accumulation of plasma cells in bone marrow. Pterostilbene (PTE) is a natural dimethylated analog of resveratrol, which has anti-oxidant, anti-inflammatory and anti-tumor properties. In the present study, we examined the anti-tumor effect of PTE on MM cell lines both in vitro and in vivo using the cell counting kit (CCK)-8, apoptosis assays, cell cycle analysis, reactive oxygen species (ROS) generation, JC-1 mitochondrial membrane potential assay, Western blotting and tumor xenograft models. The results demonstrated that PTE induces apoptosis in the H929 cell line and causes cell cycle arrest at G0/G1 phase by enhancing ROS generation and reducing mitochondrial membrane potential. The anti-tumor effect of PTE may be caused by the activation of the extracellular regulated protein kinases (ERK) 1/2 and c-Jun N-terminal kinase (JNK) signaling pathways. Additionally, mice treated with PTE by intraperitoneal injection demonstrated reduced tumor volume. Taken together, the results of this study indicate that the anti-tumor effect of PTE on MM cells may provide a new therapeutic option for MM patients.

【 授权许可】

Unknown